This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Smoking and lung cancer

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Smoking has been firmly linked to lung cancer for some time now. The first good study on this was by Doll and Hill who followed groups of GPs in the UK, and were able to show the following:

  • there was a dose response relationship between smoking and lung cancer, both on duration and amount of cigarettes smoked
  • there was no difference between the town and country
  • stopping smoking results in a continual decline in the risk

A Canadian study found that

  • 172/1,000 of male current smokers will eventually develop lung cancer
  • similar probability among female current smokers was 116/1,000
  • for those who never smoked on a regular basis the lifetime risk was substantially reduced.
    • only 13/1,000 males and 14/1,000 females in this category will develop lung cancer

Smoking is also an aetiological factor in the development of oesophageal, bladder and prostatic cancer

Smoking cessation after diagnosis materially improved overall and progression-free survival among current smokers with early-stage lung cancer (2)

  • prospective Russian cohort study found higher overall survival time among patients who quit smoking vs continued smoking (6.6vs4.8yrs, respectively; P=0.001), 5-year overall survival (60.6%vs48.6%; P=0.001) and progression-free survival (54.4%vs43.8%; P=0.004)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.